Kristen Marie Williams Sells 6,252 Shares of Pacira Biosciences Inc (NASDAQ:PCRX) Stock

Pacira Biosciences Inc (NASDAQ:PCRX) insider Kristen Marie Williams sold 6,252 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $39.49, for a total transaction of $246,891.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Kristen Marie Williams also recently made the following trade(s):

  • On Tuesday, June 4th, Kristen Marie Williams sold 2,529 shares of Pacira Biosciences stock. The stock was sold at an average price of $42.91, for a total transaction of $108,519.39.

Shares of NASDAQ PCRX traded down $0.72 on Friday, hitting $38.22. The company’s stock had a trading volume of 539,953 shares, compared to its average volume of 586,556. Pacira Biosciences Inc has a 12-month low of $35.07 and a 12-month high of $55.00. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of 131.79, a price-to-earnings-growth ratio of 1.55 and a beta of 1.15. The company has a debt-to-equity ratio of 0.99, a current ratio of 4.75 and a quick ratio of 7.83. The stock has a 50 day moving average of $42.33 and a 200-day moving average of $41.35.



Pacira Biosciences (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.27. The company had revenue of $102.60 million for the quarter, compared to the consensus estimate of $99.92 million. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The company’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.24 earnings per share. Sell-side analysts expect that Pacira Biosciences Inc will post 0.66 EPS for the current fiscal year.

A number of analysts recently commented on the stock. Wedbush set a $85.00 price objective on shares of Pacira Biosciences and gave the stock a “buy” rating in a report on Friday, June 28th. Mizuho raised shares of Pacira Biosciences from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $29.00 to $38.00 in a report on Monday, May 6th. Stifel Nicolaus set a $42.00 price objective on shares of Pacira Biosciences and gave the stock a “hold” rating in a report on Friday, August 9th. Zacks Investment Research raised shares of Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 price objective on the stock in a report on Friday, August 2nd. Finally, BidaskClub downgraded shares of Pacira Biosciences from a “hold” rating to a “sell” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $54.13.

Several large investors have recently bought and sold shares of the company. US Bancorp DE raised its position in shares of Pacira Biosciences by 9.4% in the second quarter. US Bancorp DE now owns 4,373 shares of the company’s stock valued at $190,000 after buying an additional 375 shares during the last quarter. First Mercantile Trust Co. raised its position in shares of Pacira Biosciences by 19.5% in the second quarter. First Mercantile Trust Co. now owns 4,463 shares of the company’s stock valued at $194,000 after buying an additional 728 shares during the last quarter. C M Bidwell & Associates Ltd. acquired a new position in shares of Pacira Biosciences in the second quarter valued at approximately $44,000. Legacy Capital Partners Inc. raised its position in shares of Pacira Biosciences by 2.2% in the second quarter. Legacy Capital Partners Inc. now owns 48,573 shares of the company’s stock valued at $2,112,000 after buying an additional 1,025 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Pacira Biosciences by 7.3% in the fourth quarter. Legal & General Group Plc now owns 16,652 shares of the company’s stock valued at $717,000 after buying an additional 1,129 shares during the last quarter. 99.89% of the stock is owned by institutional investors and hedge funds.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: Marijuana Stocks

Insider Buying and Selling by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.